Cellceutix reports encouraging early data from mid-stage study of Brilacidin in UC; shares ahead 4%
Mar. 8, 2017 11:36 AM ET|About: Cellceutix Corp. (CTIX)|By: Douglas W. House, SA News Editor
Thinly traded nano cap Cellceutix (OTCQB:CTIX +3.8%) perks up on the heels of its announcement of positive interim results from a Phase 2 clinical trial assessing antibiotic Brilacidin to induce remission in patients with mild-to-moderate ulcerative colitis (UC).
All 12 subjects in the first two cohorts achieved a beneficial response, while 50% achieved clinical remission at day 42. The remaining six patients achieved a partial response.
Brilacidin is a member of a new class of antibiotics called defensin-mimetics, which are modeled after host defense proteins. These are the "front line" of defense in the human immune system. An oral rinse formulation is in Phase 2 development for the treatment of chemoradiation-associated oral mucositis.
http://seekingalpha.com/news/3249599-cellceut...email_link
Mar. 8, 2017 11:36 AM ET|About: Cellceutix Corp. (CTIX)|By: Douglas W. House, SA News Editor
Thinly traded nano cap Cellceutix (OTCQB:CTIX +3.8%) perks up on the heels of its announcement of positive interim results from a Phase 2 clinical trial assessing antibiotic Brilacidin to induce remission in patients with mild-to-moderate ulcerative colitis (UC).
All 12 subjects in the first two cohorts achieved a beneficial response, while 50% achieved clinical remission at day 42. The remaining six patients achieved a partial response.
Brilacidin is a member of a new class of antibiotics called defensin-mimetics, which are modeled after host defense proteins. These are the "front line" of defense in the human immune system. An oral rinse formulation is in Phase 2 development for the treatment of chemoradiation-associated oral mucositis.
http://seekingalpha.com/news/3249599-cellceut...email_link
